Cardio IQ® CYP2C19 Genotype
Also known as: CardioIQ®, CYP2C19 Genotype
Use
Patients carrying one or two copies of nonfunctional CYP2C19 alleles may not receive the full benefit of clopidogrel (Plavix®), and may benefit from alternative dosing strategies or another antiplatelet agent. Although the CYP2C19 genotype–clopidogrel response association is well-established in patients with acute coronary syndrome (ACS) undergoing PCI, evidence suggests similar relevance in neurovascular indications. Interpretation should consider clinical and family history and physical findings.
Special Instructions
Not provided.
Limitations
This is a targeted genotyping assay; it does not detect deletions or novel or rare CYP2C19 variants. Not all variability in clopidogrel response is captured by genotype—other factors include age, BMI, CKD, diabetes, concomitant proton pump inhibitors, and others. Results should be interpreted alongside clinical context.
Methodology
PCR-based (PCR)
Biomarkers
CYP2C19
Gene
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
4 mL
Minimum Volume
2 mL
Container
EDTA (lavender‑top) tube
Collection Instructions
4 mL whole blood collected in an EDTA (lavender‑top) tube; follow normal phlebotomy procedures.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 8 days |
| Refrigerated | 8 days |
| Frozen | 30 days |
Other tests from different labs that may be relevant